
Contents

| | |
|---|----|
| An Emerging Role for Anti-inflammatory Agents for Chemoprevention. | 1 |
| References | 4 |
| Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia . . . | 7 |
| 1 Molecular Basis of Colorectal Adenoma and Carcinoma | 9 |
| 1.1 Genetic Basis of Adenoma-Carcinoma Sequence. | 9 |
| 1.2 Adenomatous Polyposis Coli. | 10 |
| 1.3 The Microsatellite Instability Pathway in CRC | 11 |
| 1.4 The Epigenetic Pathway in CRC | 12 |
| 1.5 COX-2/mPGES-1 Pathway | 12 |
| 1.6 Prostaglandin Transporters in CRC | 16 |
| 1.7 Epidermal Growth Factor Receptor Pathway. | 16 |
| 1.8 Peroxisome Proliferator-Activated Receptors. | 17 |
| 1.9 Tumor Microenvironment in Colorectal Carcinogenesis | 18 |
| 2 COX-2 Gene Expression in CRC | 18 |
| 2.1 Transcriptional Regulation | 19 |
| 2.2 Post-transcriptional Regulation and the 3' Untranslated Region. | 21 |
| 2.3 AU-Rich Elements and ARE-Binding Proteins | 22 |
| 2.4 MicroRNAs | 26 |
| 3 Conclusions | 29 |
| References | 30 |
| Mode of Action of Aspirin as a Chemopreventive Agent. | 39 |
| 1 Introduction | 41 |
| 2 Mechanisms of Action of Aspirin | 42 |
| 2.1 Historical Overview of Aspirin and its Mechanism of Action (Box. 1). | 42 |
| 2.2 Insights into the Mechanism of Inhibition of COXs by Aspirin. | 44 |
| 3 Pharmacology/Pharmacokinetic of Aspirin | 49 |

| | | |
|-----|---|----|
| 3.1 | COX-Isozyme Selectivity in Vitro | 49 |
| 3.2 | Pharmacokinetic | 50 |
| 3.3 | Determinants of Achieved COX-Isozyme Selectivity by Clinical Doses of Aspirin. | 52 |
| 4 | Role of Platelets in Tumorigenesis | 53 |
| 4.1 | Platelet-Mediated Mechanisms in Tumorigenesis and Metastasis. | 53 |
| 4.2 | Role of Platelet COX-1 in Aspirin Chemoprevention. | 56 |
| 5 | COX-Independent Mechanisms of Aspirin Chemoprevention | 57 |
| 5.1 | Inhibition of NF- κ B | 57 |
| 5.2 | Interruption of Extracellular Signal-Regulated Kinases | 59 |
| 5.3 | Induction of Apoptosis by Caspase Activation | 59 |
| 5.4 | Inhibition of Wnt/ β -Catenin Pathway. | 59 |
| 6 | Aspirin-Mediated Acetylation of Extra-COX Proteins | 59 |
| 7 | Conclusions | 60 |
| | References | 61 |

Coxibs: Pharmacology, Toxicity and Efficacy

| | |
|---|-----------|
| in Cancer Clinical Trials | 67 |
| 1 Introduction | 69 |
| 2 Pharmacology of tNSAIDs and Coxibs | 76 |
| 3 Efficacy of Coxibs in CRC Chemoprevention Trials | 77 |
| 4 CV Toxicity of Coxibs. | 80 |
| 4.1 Risk Estimates: Data from Trials and Observational Studies. | 80 |
| 4.2 Mechanisms of CV Toxicity of Coxibs | 83 |
| 4.3 Ongoing Randomized Clinical Trials with Coxibs/NSAIDs. | 85 |
| 5 Conclusions and Perspectives | 86 |
| References | 87 |

COX-2 Active Agents in the Chemoprevention

| | |
|---------------------------------------|-----------|
| of Colorectal Cancer | 95 |
| References | 102 |

New NSAID Targets and Derivatives for Colorectal

| | |
|--|------------|
| Cancer Chemoprevention | 105 |
| 1 Introduction | 106 |
| 2 Targeting COX-2. | 109 |
| 3 COX-Independent Targets | 110 |
| 3.1 Inhibition of cGMP PDEs. | 110 |
| 3.2 Generation of Reactive Oxygen Species. | 112 |
| 3.3 Downregulation of Survivin | 113 |
| 3.4 Other COX-Independent Targets | 114 |
| 4 Conclusions | 115 |
| References | 117 |

Aspirin in Prevention of Sporadic Colorectal Cancer: Current Clinical Evidence and Overall Balance

| | |
|---|------------|
| of Risks and Benefits | 121 |
| 1 Introduction | 122 |
| 2 Aspirin in Prevention of Colorectal Cancer. | 122 |
| 2.1 Observational Studies. | 122 |
| 2.2 Randomised Controlled Trials | 125 |
| 3 Effects on Other Cancers | 131 |
| 4 Overall Balance of Risk and Benefit | 135 |
| 5 Summary and Outstanding Issues | 137 |
| References | 139 |

Nutritional Agents with Anti-inflammatory Properties in Chemoprevention of Colorectal Neoplasia

| | |
|--|------------|
| 1 Naturally Occurring Substances Used as Pharmaceutical Preparations—‘Nutraceuticals’ | 143 |
| 2 Anti-inflammatory Agents for Prevention and Treatment of CRC | 145 |
| 3 Anti-inflammatory Nutraceuticals with Evidence of Anti-CRC Activity. | 145 |
| 3.1 Omega-3 PUFAs | 145 |
| 3.2 Curcumin | 149 |
| 3.3 Resveratrol | 151 |
| 3.4 Other Dietary Polyphenols | 152 |
| 3.5 Other Natural Anti-inflammatory Agents with CRC Chemopreventative Efficacy | 152 |
| 4 Summary | 153 |
| References | 153 |

Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC)

| | |
|--|------------|
| 1 Introduction | 157 |
| 2 CAPP1 | 163 |
| 2.1 CAPP1 Trial Design | 164 |
| 2.2 CAPP1 Endpoint Ascertainments. | 165 |
| 2.3 CAPP1 Laboratory and Statistical Methods. | 165 |
| 2.4 CAPP1 Results | 166 |
| 2.5 CAPP1 Toxicity | 168 |
| 2.6 CAPP1 Conclusions. | 169 |
| 3 Chemoprevention in Lynch Syndrome: CAPP2. | 170 |
| 3.1 CAPP2 Trial Design | 172 |
| 3.2 CAPP2 Endpoint Ascertainments. | 172 |
| 3.3 CAPP2 Statistical Methods | 172 |
| 3.4 CAPP2 Results | 175 |
| 3.5 CAPP2 Toxicity | 178 |
| 3.6 CAPP2 Discussion. | 179 |

| | | |
|---|----------------------|-----|
| 4 | CAPP3 | 180 |
| 5 | Conclusion | 180 |
| | References | 181 |

Prospects for Chemoprevention of Colorectal Neoplasia

Emerging Role of Anti-Inflammatory Drugs

Chan, A.T.; Detering, E. (Eds.)

2013, VIII, 184 p., Hardcover

ISBN: 978-3-642-30330-2